Apogee Therapeutics Inc.

Apogee Therapeutics Inc.

APGE - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$8.4B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Apogee Therapeutics Inc.Apogee Therapeutics Inc.-31.1--25%--
$135.00

Target Price by Analysts

0.1% downsideApogee Therapeutics Target Price DetailsTarget Price
$2.02

Current Fair Value

98.5% downside

Overvalued by 98.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$8.40 Billion
Enterprise Value$8.30 Billion
Earnings per Share$-4.22
Beta0.34
Outstanding Shares75,443,496

Return

Return on Equity-24.64%ROE
Return on Assets-22.04%
Return on Invested Capital-23.88%

Valuation & Multiples

P/E Ratio-31.12P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio9.0Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-26.78
Enterprise Value to Net Income-29
Total Debt to Enterprise0
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 17, 2026
EPS Estimate
$-1.10
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
November 9, 2026
EPS Estimate
$-1.14
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 4.31, the ratio is above 1, so institutions hold more puts than calls. That is a more cautious stance.

Put/Call Ratio4.3137▲ 390.71%
Total Calls270,000▼ 69.46%
Total Puts1,164,700▲ 223.98%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %90.15%▼ 23.33%
Total Invested$8.99B▲ 35.37%
Investors Holding311▲ 71.00%

About Apogee Therapeutics Inc.

Apogee Therapeutics Insider Information FAQ

Stockcircle tracks 4 top investors with a current 13F position in Apogee Therapeutics. Notable holders include ARK Invest. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 1 top investor increased or opened positions and 2 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 10 open-market insider sales for Apogee Therapeutics in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.